Imeglimin is an experimental drug being developed as an oral anti-diabetic. It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis increase muscle glucose uptake and restore normal insulin secretion.
This page contains content from the copyrighted Wikipedia article "Imeglimin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
